The MAIN-COMPARE Registry

Similar documents
The MAIN-COMPARE Study

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

PROMUS Element Experience In AMC

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

Unprotected LM intervention

Count Down to COMBAT

LM stenting - Cypher

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Alex versus Xience Registry Preliminary report

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event. The DES LATE Trial

Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial)

Journal of the American College of Cardiology Vol. 57, No. 21, by the American College of Cardiology Foundation ISSN /$36.

Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected left main coronary artery

Lessons learned From The National PCI Registry

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

DECISION-CTO. Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion. Seung-Jung Park, MD., PhD.

New Generation Drug- Eluting Stent in Korea

Abstract Background: Methods: Results: Conclusions:

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Long-Term Safety and Efficacy of Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease

Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Journal of the American College of Cardiology Vol. 57, No. 12, by the American College of Cardiology Foundation ISSN /$36.

Incidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

PCI for Long Coronary Lesion

Supplementary Online Content

Percutaneous Intervention of Unprotected Left Main Disease

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

PCI vs. CABG From BARI to Syntax, Is The Game Over?

Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

Supplementary Table S1: Proportion of missing values presents in the original dataset

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES

Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

New Insight about FFR and IVUS MLA

Δημήτριος Αγγοσράς, FETCS

Declaration of conflict of interest. Nothing to disclose

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome

Perspective of LM stenting with Current registry and Randomized Clinical Data

Supplementary Material to Mayer et al. A comparative cohort study on personalised

Bern-Rotterdam Cohort Study

BMS vs. DES vs. CABG

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

Hyeon-Cheol Gwon, On the behalf of SMART-DATE trial investigators ACC LBCT 2018

FFR-guided Jailed Side Branch Intervention

Rationale for Percutaneous Revascularization ESC 2011

Korea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea

Stent Fracture and Longitudinal Compression on CT Angiography between the

1. Diabetes mellitus (DM) is associated with worse clinical and angiographic outcomes even in acute myocardial Infarction (AMI) patients.

Left Main and Bifurcation Summit I. Lessons from European LM Studies

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Percutaneous Coronary Interventions Without On-site Cardiac Surgery

Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials

Between Coronary Angiography and Fractional Flow Reserve

PCI for LMCA lesions A Review of latest guidelines and relevant evidence

FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators

Medicine OBSERVATIONAL STUDY

Upgrade of Recommendation

Surgery Grand Rounds

COMBAT- Revised Protocol

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

Journal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.

Left Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD

Coronary Artery Disease: Revascularization (Teacher s Guide)

Osler Journal Club Outcomes Research

Original Article. Introduction. Korean Circulation Journal

Acute kidney injury and outcomes in acute decompensated heart failure in Korea

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.

Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions

Drug Eluting Stents: Bifurcation and Left Main Approach

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

eucalimus - First Experience

DECISION - CTO. optimal Medical Treatment in patients with. Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators

Supplementary Online Content

What do the guidelines say?

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Supplementary Appendix

Importance of the third arterial graft in multiple arterial grafting strategies

Coronary Heart Disease in Patients With Diabetes

Prevention of Coronary Stent Thrombosis and Restenosis

Single Center Consecutive Registry Of The New Atrium Flyer Coronary Stent System

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

Coronary Artery Bypass Grafting vs. Drug-Eluting Stent Implantation for Multivessel Disease in Patients with Chronic Kidney Disease

Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality

Long-Term Clinical Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents for Patients With Unprotected Left Main Coronary Artery Disease

Fractional Flow Reserve: Review of the latest data

Summary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A

The Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System

Transcription:

Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis: COMparison of Percutaneous Coronary Angioplasty versus Surgical REvascularization from Multi-Center Registry: The MAIN-COMPARE Registry Co-Principal Investigators: Seung-Jung Park, MD, PhD, Ki-Bae Seung, MD, PhD for the MAIN-COMPARE Study investigators

MAIN-COMPARE Registry Stenting (BMS vs. DES) vs. January, 2000 Wave I (Era of BMS) LMCA disease (N=775) BMS (N=318) (N=448) Second quarter, 2003 Wave II (Era of DES) LMCA disease (N=1536) June, 2006 Total (N=2240) DES (N=784) PCI (N=1102) (N=690) (N=1138)

Study Administration P.I. : Seung-Jung Park, MD, PhD, Asan Medical Center Ki-Bae Seung, MD, PhD, Kagnam St Mary s Hospital Sponsors: The Korean Society of Interventional Cardiology CardioVasuclar Research Foundation (CVRF) Investigating centers: - Asan Medical Center, Seoul, Korea - Kangnam St Mary s Hospital, Seoul, Korea - Yoido St Mary s Hospital, Seoul, Korea - Kyungpook National University Hospital, Daegu, Korea - Gachon University Gil Medical Center, Incheon, Korea - Seoul National University Hospital, Seoul, Korea - Seoul National University Bundang Hospital, Seongnam, Korea - Samsung Medical Center, Seoul, Korea - Ajou University Hospital, Suwon, Korea - Yonsei University Medical Center, Seoul, Korea - Chonnam National Univeristy Hospital, Gwangju, Korea - Chung-Nam University Hospital, Daejon, Korea Data analysis and management: CVRF and Clinical Research Center in AMC Local independent event committee: University of Ulsan Medical College

Background To date, has been traditionally regarded as the gold standard therapy for the treatment of unprotected left main coronary artery (LMCA) stenosis. LMCA stenosis also might be considered as a suitable target for coronary stenting because of its large caliber, short lesion length and lack of tortuosity.

Background The availability of DES has improved the efficacy outcomes, as compared to BMS, and prompted re-evaluation of the optimal strategy for LMCA disease. There have been no prospective, randomized clinical trials involving long-term evaluation of the percutaneous or surgical treatment for unprotected LMCA disease.

Objective To compare long-term outcomes in patients with unprotected LMCA disease, who underwent or stenting in multi-centers to provide a very large clinical registry from Korea.

Enrollment Criteria Inclusion Criteria Patients with unprotected left main disease (>50% by visual estimation) who underwent stenting or isolated (** The LMCA is considered unprotected if there are no patent coronary artery bypass grafts to the LAD or the LCX) Exclusion Criteria Prior Concomitant valvular or aortic surgery ST-elevation MI Cardiogenic shock at presentation

Primary Outcome Measures Death Composite outcomes of death, Q-wave MI, and stroke Target-vessel Revascularization

Databases Baseline clinical, angiographic, procedural or operative data, and outcomes of interest were collected using the dedicated internet-based reporting system. All outcomes of interest were confirmed by source documentations reported at each hospital and were centrally adjudicated by the local events committee at the University of Ulsan College of Medicine, Asan Medical Center, Seoul. For validation of complete follow-up data, information about vital status was obtained through July 15, 2007, from the National Population Registry of the Korea National Statistical Office using a unique personal identification number.

Statistical Analysis To reduce treatment selection biases and potential confounding in an observational study and approximate a randomized trial, we performed rigorous adjustment for significant differences in characteristics of patients by use of the propensity-score matching. Using greedy nearest-neighbor matching algorithm, we created a propensity-score-matched pairs (a 1:1 match). Specifically, we sought to match each patient with stenting to one with who had a propensity score that was identical to 5 digits. If this could not be done, the algorithm then proceeded sequentially to the lowest digit match (a 4-, 3-, 2-, or 1-digit) on propensity score to make next-best matches. For each of concurrent comparisons (Wave I and Wave II), a new propensity score for PCI versus was incorporated for each analysis.

Results

PCI patients (N=1102) Primary reason for PCI Patient or Doctor preference in the absence of high surgical risk Not-eligible (not operable or high risk) for (High-surgical risk) Old age 80 years and poor performance Limited life expectancy Current malignancy Concurrent severe medical illness No suitable bypass conduits 1073 (97%) 29 (3%) 8 3 2 12 4

Procedural Characteristics for and PCI Variable Group Off-pump surgery (%) At least one arterial conduit (%) IMA to LAD Graft (%) Grafts / Patients (Mean ± SD) PCI Group Bare-metal stents(%) Drug-eluting stents (%) Sirolimus stents of DES (%) Paclitaxel stents of DES (%) Number of stents at LM site Length of stents at LM site Average stent diameter at LM site (n = 1102) 42 98 98 2.9±1.0 - - - - PCI (n = 1138) - - - - 29 71 (77) (23) 1.2±0.5 28±21 3.5±0.4

Baseline Characteristics Variable Stents (n=1102) (n=1138) P Value Demographic characteristics Age (yr) <0.001 Median 62 64 Interquartile range 52-70 57-70 Male sex (%) 70.7 72.9 0.24 Cardiac or Coexisting conditions (%) Diabetes mellitus Any diabetes 29.7 34.7 0.01 Requiring insulin 6.8 8.2 0.22 Hypertension 49.5 49.4 0.94 Hyperlipidemia 28.5 32.6 0.04 Current smoker 25.6 29.8 0.03

Baseline Characteristics Variable Stents (n=1102) (n=1138) P Value Previous coronary angioplasty 18.1 11.0 <0.001 Previous myocardial infarction 8.1 11.6 0.005 Previous congestive heart failure 2.5 3.3 0.21 Chronic obstructive pulmonary disease 2.0 2.0 0.97 Cerebrovascular disease 7.1 7.3 0.84 Peripheral vascular disease 1.5 5.4 <0.001 Renal failure 2.7 3.0 0.71 Ejection fraction (%) <0.001 Median 62 60 Interquartile range 57-67 52-66

Baseline Characteristics Variable Stents (n=1102) (n=1138) P Value Electrocardiographic findings 0.53 Sinus rhythm 97.8 97.1 Atrial fibrillation 2.0 2.7 Other 0.2 0.2 Clinical indication (%) <0.001 Silent ischemia 3.0 2.2 Chronic stable angina 32.0 19.9 Unstable angina 55.2 68.1 NSTEMI 9.8 9.8

Baseline Characteristics Variable Stents (n=1102) (n=1138) P Value Angiographic characteristics (%) Extent of diseased vessel <0.001 Left main only 25.2 6.2 Left main plus single-vessel ds 24.0 10.5 Left main plus double-vessel ds 26.0 26.3 Left main plus triple-vessel ds 24.8 57.0 Right coronary artery disease 35.9 70.7 <0.001 Restenotic lesion 2.9 1.2 0.005

After Propensity-Matching to approximate a randomized trial

Baseline Characteristics of Propensity-Matched Patients (542 pairs) Age (yr) Median Interquartile range Male sex (%) Diabetes mellitus Any diabetes Requiring insulin Hypertension Hyperlipidemia Current smoker Variable Demographic characteristics Cardiac or Coexisting conditions (%) Stents (n=542) 64 56-71 71.6 32.7 7.6 49.5 29.4 29.4 (n=542) 64 56-70 71.2 33.0 7.9 50.0 30.1 30.1

Baseline Characteristics of Propensity-Matched Patients Renal failure Ejection fraction (%) Median Interquartile range Variable Previous coronary angioplasty Previous myocardial infarction Previous congestive heart failure Chronic obstructive pulmonary disease Cerebrovascular disease Peripheral vascular disease Stents (n=542) 14.8 9.0 2.9 2.6 7.4 2.0 3.7 61 54-66 (n=542) 15.1 10.0 3.0 2.2 6.6 2.0 3.9 61 55-66

Baseline Characteristics of Propensity-Matched Patients Sinus rhythm Atrial fibrillation Other Clinical indication (%) Silent ischemia Chronic stable angina Unstable angina NSTEMI Variable Electrocardiographic findings Stents (n=542) 97.6 2.4 0.0 2.8 29.2 57.4 10.7 (n=542) 96.7 3.1 0.2 2.7 28.4 57.9 11.1

Baseline Characteristics of Propensity-Matched Patients Left main only Restenotic lesion Variable Angiographic characteristics (%) Extent of diseased vessel Left main plus single-vessel disease Left main plus double-vessel disease Left main plus triple-vessel disease Right coronary artery disease Stents (n=542) 11.8 17.0 31.7 39.5 53.7 1.9 (n=542) 11.1 16.2 33.9 38.7 53.7 1.8

Results Outcomes of Propensity- Matched Cohort (N=542) Stent vs.

Death upto 3 Year (Paired Kaplan-Meier Analysis) 92.2 92.1 P=0.45 HR 1.18 (0.77-1.80) PCI KB Seung & SJ Park et al. N Engl J Med. 2008 Mar

Death, Q-MI, or Stroke upto 3 Year (Paired Kaplan-Meier Analysis) 90.8 90.7 P=0.61 HR 1.10 (0.75-1.62) PCI KB Seung & SJ Park et al. N Engl J Med. 2008 Mar

TVR upto 3 Year (Paired Kaplan-Meier Analysis) 97.4 87.4 P<0.001 HR 4.76 (2.80-8.11) PCI KB Seung & SJ Park et al. N Engl J Med. 2008 Mar

After Propensity-Matching in BMS era (N=207) BMS vs.

Baseline Characteristics of Propensity-Matched Patients (207 pairs) Variable Demographic characteristics Age (yr) Median Interquartile range Male sex (%) Cardiac or Coexisting conditions (%) Diabetes mellitus Any diabetes Requiring insulin Hypertension Hyperlipidemia Current smoker BMS (n=207) 61 51-69 72.0 26.1 4.9 44.9 27.1 28.5 (n=207) 61 53-67 71.0 26.6 5.3 45.1 27.2 28.2

Baseline Characteristics of Propensity-Matched Patients Renal failure Ejection fraction (%) Median Interquartile range Variable Previous coronary angioplasty Previous myocardial infarction Previous congestive heart failure Chronic obstructive pulmonary disease Cerebrovascular disease Peripheral vascular disease BMS (n=207) 14.0 9.7 2.4 2.1 6.7 1.0 1.9 61 57-67 (n=207) 14.6 10.5 2.8 1.9 6.3 1.0 2.4 61 56-66

Baseline Characteristics of Propensity-Matched Patients Sinus rhythm Atrial fibrillation Other Clinical indication (%) Silent ischemia Chronic stable angina Unstable angina NSTEMI Variable Electrocardiographic findings BMS (n=207) 97.6 2.4 0.0 2.9 16.6 69.7 10.8 (n=207) 97.1 2.9 0.0 3.4 16.4 69.6 10.6

Baseline Characteristics of Propensity-Matched Patients Left main only Restenotic lesion Variable Angiographic characteristics (%) Extent of diseased vessel Left main plus single-vessel disease Left main plus double-vessel disease Left main plus triple-vessel disease Right coronary artery disease BMS (n=207) 21.3 29.0 33.8 15.9 29.5 2.0 (n=207) 21.3 29.0 33.8 15.9 29.5 2.4

Results Outcomes of Propensity- Matched Cohort (N=207) BMS vs.

Death upto 3 Year (Paired Kaplan-Meier Analysis) 91.7 91.6 P=0.91 HR 1.04 (0.59-1.83) BMS KB Seung & SJ Park et al. N Engl J Med. 2008 Mar

Death, Q-MI, or Stroke upto 3 Year (Paired Kaplan-Meier Analysis) 91.1 89.8 P=0.59 HR 0.86 (0.50-1.49) BMS KB Seung & SJ Park et al. N Engl J Med. 2008 Mar

TVR upto 3 Year (Paired Kaplan-Meier Analysis) 98.9 82.5 P<0.001 HR 10.70 (3.80-29.90) BMS KB Seung & SJ Park et al. N Engl J Med. 2008 Mar

After Propensity-Matching in DES era (N=396) DES vs.

Baseline Characteristics of Propensity-Matched Patients (396 pairs) Variable Demographic characteristics Age (yr) Median Interquartile range Male sex (%) Cardiac or Coexisting conditions (%) Diabetes mellitus Any diabetes Requiring insulin Hypertension Hyperlipidemia Current smoker DES (n=396) 66 57-72 71.5 36.0 10.1 52.3 32.6 26.3 (n=396) 66 58-70 71.7 36.9 10.9 53.0 33.6 25.5

Baseline Characteristics of Propensity-Matched Patients Renal failure Ejection fraction (%) Median Interquartile range Variable Previous coronary angioplasty Previous myocardial infarction Previous congestive heart failure Chronic obstructive pulmonary disease Cerebrovascular disease Peripheral vascular disease DES (n=396) 14.4 8.8 3.0 2.8 8.0 2.5 5.3 60 55-66 (n=396) 14.4 9.3 3.3 2.5 7.3 3.3 4.8 60 56-66

Baseline Characteristics of Propensity-Matched Patients Sinus rhythm Atrial fibrillation Other Clinical indication (%) Silent ischemia Chronic stable angina Unstable angina NSTEMI Variable Electrocardiographic findings DES (n=396) 97.7 2.3 0.0 2.3 30.1 57.8 9.8 (n=396) 96.5 3.0 0.5 2.8 28.8 57.8 10.6

Baseline Characteristics of Propensity-Matched Patients Variable Angiographic characteristics (%) Extent of diseased vessel Left main only Left main plus single-vessel disease Left main plus double-vessel disease Left main plus triple-vessel disease Right coronary artery disease Restenotic lesion DES (n=396) 5.8 12.4 28.0 52.8 65.9 1.8 (n=396) 5.8 11.6 30.0 53.0 66.9 1.3

Results Outcomes of Propensity- Matched Cohort (N=396) DES vs.

Death upto 3 Year (Paired Kaplan-Meier Analysis) 93.1 91.0 P=0.26 HR 1.36 (0.80-2.30) DES KB Seung & SJ Park et al. N Engl J Med. 2008 Mar

Death, Q-MI, or Stroke upto 3 Year (Paired Kaplan-Meier Analysis) 92.0 88.5 P=0.15 HR 1.40 (0.88-2.22) DES KB Seung & SJ Park et al. N Engl J Med. 2008 Mar

TVR upto 3 Year (Paired Kaplan-Meier Analysis) 98.4 90.7 P<0.001 HR 5.96 (2.51-14.10) DES KB Seung & SJ Park et al. N Engl J Med. 2008 Mar

Conclusions from MAIN-COMPARE Registry In Korea, PCI for Unprotected LM disease has been exclusively performed in the low-surgical patients for, implying that PCI for LMCA disease is common practice comparable to. For the treatment of unprotected LMCA disease, stenting, both BMS and DES, showed equivalent long-term mortality and serious ischemic complications (death, Q-wave MI, or stroke) as.

Conclusions from MAIN-COMPARE Registry Despite significant reduction of TVR with DES compared to BMS, was still more effective in reducing TVR than stenting. These findings should be ascertained and refuted through large, randomized clinical trials.